Using human genetics to predict the effects and side-effects of drugs

Current Opinion in Lipidology

Volumn 27, Issue 2, 2016, Pages 105-111

  Stender, Stefan ^a   Tybjærg Hansen, Anne ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

genetics; Keywords drug targets; LDL cholesterol; Mendelian randomization; triglycerides

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROTEIN; PROTEIN ANGPTL3; PROTEIN APOC3; PROTEIN NPC1L1; PROTEIN PCSK9; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT;

CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; ENZYME BLOOD LEVEL; GENE MUTATION; HUMAN; HUMAN GENETICS; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ANIMAL; DNA SEQUENCE; GENETIC ASSOCIATION STUDY; GENETICS; HYPERCHOLESTEROLEMIA; MEDICAL GENETICS; PHARMACOGENETIC VARIANT; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; GENETIC ASSOCIATION STUDIES; GENETICS, MEDICAL; HUMANS; HYPERCHOLESTEROLEMIA; PHARMACOGENOMIC VARIANTS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84960402588     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000280     Document Type: Review

References (46)

1. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2012; 380: 2095-2128
3. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet 2014; 384: 618-625
4. Gouni-Berthold I, Berthold HK. Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia. Atheroscler Suppl 2015; 18: 28-34
5. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351-361
6. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65: 1552-1561
7. Lauridsen BK, Stender S, Frikke-Schmidt R, et al. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J 2015; 36: 1601-1608
8. Stitziel NO, Won HH, Morrsison, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014; 371: 2072-2082
9. http: //www.merck.com/product/usa/pi-circulars/z/zetia/zetia-pi.pdf. [Accessed 30 November 2015]
10. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272
12. Giugliano RP, Sabatine MS. Are PCSK9 Inhibitors the next breakthrough in the cardiovascular field?. J Am Coll Cardiol 2015; 65: 2638-2651
13. Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network metaanalysis. Eur Heart J 2015. [Epub ahead of print]. doi: 10.1093/eurheartj/ehv563 ehv563
14. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-523
15. Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 2014; 25: 161-168
16. Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol 2015; 9: 217-225
17. Hooper AJ, Burnett JR, Watts GF. Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. Circ Res 2015; 116: 193-205
18. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-635
19. Jorgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated nonfasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34: 1826-1833
20. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427-436
21. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371: 32-41.
22. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322: 1702-1705
23. Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371: 22-31
24. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371: 2200-2206
25. Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015; 373: 438-447
26. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 2009; 119: 70-79
27. Koster A, Chao YB, Mosior M, et al. Transgenic angiopoietin-like (angptl) 4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005; 146: 4943-4950
28. Wang Y, Gusarova V, Banfi S, et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res 2015; 56: 1296-1307
29. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res 2015; 56: 1308-1317
30. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853
31. Graham MJ, Viney N, Crooke R, Tsimikas S. Antisense inhibition of apolipoprotein( a) to lower plasma lipoprotein(a) levels in humans. J Lipid Res 2015. [Epub ahead of print]
32. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein( a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386: 1472-1483
33. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101: 1907-1912
34. Andersen R, Wittrup HH, Tybjærg-Hansen A, et al. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 2003; 41: 1972-1982
35. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-offunction mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299: 2524-2532
36. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122
37. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099
38. https: //investor.lilly.com/releasedetail.cfm?releaseid 936130. [Accessed 30 November 2015]
39. Johannsen TH, Frikke-Schmidt R, Schou J, et al. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 2012; 60: 2041-2048
40. Cougnard-Gregoire A, Delyfer MN, Korobelnik JF, et al. Elevated high-density lipoprotein cholesterol and age-related macular degeneration: the Alienor study. PloS One 2014; 9: e90973
41. Cheng CY, Yamashiro K, Chen LJ, et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat Commun 2015; 6: 6063
42. Packard CJ, O Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A (2) as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-1155
43. Maiolino G, Bisogni V, Rossi GP. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol 2015; 7: 609-620
44. O Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312: 1006-1015
45. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370: 1702-1711
46. Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase A (2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 2013; 62: 1966-1976